| 1445 |
National Cancer Institute |
Html |
en |
Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Health Professional Version |
Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck. |
| Oral Mucositis section | 0.646528 |
| oral lesions | 0.713241 |
| permanent oral complications | 0.655143 |
| especially oral mucositis | 0.68535 |
| hematopoietic stem cell | 0.672562 |
| severe oral mucositis | 0.704955 |
| normal oral function. | 0.655722 |
| oral infection | 0.648431 |
| oral anatomic structures | 0.655446 |
| cancer therapy | 0.661822 |
| oral pain | 0.661419 |
| oral tissues | 0.687688 |
| oral management | 0.671998 |
| oral mucositis | 0.976928 |
| acute oral complications | 0.672602 |
| oral complications | 0.869367 |
| comprehensive oral care | 0.65304 |
| cancer patients | 0.684573 |
| oral manifestations | 0.663979 |
| Poor oral health | 0.644837 |
| oral health | 0.672192 |
| local oral infections | 0.645116 |
| oral mucosal inflammation | 0.655414 |
| necessary oral care | 0.650666 |
| oral mucositis index | 0.679834 |
|
| severe oral morbidity | 0.658041 |
| item oral mucositis | 0.6536 |
| oral mucosa | 0.692735 |
| oral care | 0.722741 |
| oral mucosal changes | 0.646052 |
| oral mucositis guidelines | 0.662614 |
| radiation-induced oral mucositis | 0.65347 |
| oral mucosal tissues | 0.663688 |
| Severe oral toxicities | 0.662231 |
| ulcerative oral mucositis | 0.758526 |
| chemotherapy-induced oral mucositis | 0.687692 |
| common oral complications | 0.674757 |
| oral mucosal healing | 0.660629 |
| comprehensive oral hygiene | 0.655656 |
| oral hygiene | 0.74644 |
| oral status | 0.661747 |
| oral mucosal integrity | 0.669711 |
| nonmedicated oral care | 0.646962 |
| acute oral GVHD | 0.644918 |
| oral mucosal toxicity | 0.664745 |
| oral toxicities | 0.662473 |
| oral cavity | 0.705394 |
| cancer | 0.687828 |
| oral disease | 0.662382 |
|
CLICK HERE |
| 1540 |
National Cancer Institute |
Html |
en |
Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version |
Information about how to weigh the strength of the evidence obtained in human studies of integrative, alternative, and complementary therapies for cancer. |
| strength | 0.674769 |
| evidence score | 0.330764 |
| clinical details | 0.253336 |
| strongest endpoint | 0.346454 |
| weak study design | 0.389561 |
| PDQ cancer information | 0.609434 |
| PDQ information | 0.33766 |
| Best Case Series | 0.34796 |
| clinical trials | 0.245761 |
| cancer information summary | 0.520348 |
| human studies | 0.415104 |
| breast cancer prevention | 0.370124 |
| numeric scale | 0.249195 |
| randomized trial | 0.254175 |
| study types | 0.251887 |
| study design | 0.95862 |
| design categories yields | 0.398085 |
| NCI’s PDQ | 0.357199 |
| cancer treatment studies | 0.394746 |
| PDQ Adult Treatment | 0.532483 |
| NCI PDQ cancer | 0.476778 |
| weakest design | 0.286828 |
| statistical strength | 0.648901 |
| complementary therapies | 0.394252 |
| human cancer | 0.391957 |
|
| proper assessment | 0.249946 |
| Therapies Editorial Board | 0.336527 |
| PDQ Integrative | 0.333821 |
| strongest design | 0.2759 |
| different treatments | 0.250238 |
| clinical findings | 0.245005 |
| case series | 0.380662 |
| progressive alphabetic scale | 0.362349 |
| similar results | 0.25211 |
| therapeutic endpoint | 0.358766 |
| Cause-specific mortality | 0.243515 |
| endpoint | 0.41291 |
| individual case reports | 0.382311 |
| particular treatments | 0.266483 |
| total mortality | 0.246905 |
| scientific strength | 0.586275 |
| National Cancer Institute | 0.778424 |
| Editorial Board | 0.404104 |
| PDQ documents | 0.331784 |
| various types | 0.248384 |
| anecdotal reports | 0.254781 |
| cancer-related images | 0.244704 |
| tumor response | 0.253792 |
| stronger study design | 0.404144 |
|
CLICK HERE |
| 1743 |
National Cancer Institute |
Html |
en |
Photodynamic Therapy for Cancer |
A fact sheet that explains photodynamic therapy, how it is administered, and indications and side effects of treatment. |
| cancer treatment | 0.467161 |
| skin cancer | 0.463524 |
| agent | 0.509208 |
| necessary nutrients | 0.453814 |
| blood cancers | 0.455343 |
| activating light | 0.500969 |
| cutaneous T-cell lymphoma | 0.497644 |
| surface tumors | 0.462582 |
| body | 0.47526 |
| different areas | 0.455534 |
| light sources | 0.464075 |
| healthy tissue | 0.483908 |
| bright indoor light | 0.598285 |
| U.S. Food | 0.516598 |
| specific wavelength | 0.502289 |
| certain cancers | 0.465708 |
| patients | 0.455008 |
| blood cells | 0.468142 |
| photosensitizing agent | 0.45652 |
| non-small cell lung | 0.667463 |
| photosensitizer | 0.466135 |
| symptoms | 0.456503 |
| particular type | 0.455996 |
| direct sunlight | 0.514024 |
| specific type | 0.457687 |
|
| treatment | 0.479989 |
| esophageal cancer | 0.492936 |
| photodynamic therapy | 0.576544 |
| nearby healthy tissue | 0.481898 |
| skin | 0.463697 |
| Drug Administration | 0.510947 |
| active form | 0.454418 |
| cancer cells | 0.690083 |
| fiber optic cable | 0.49481 |
| Barrett esophagus | 0.454031 |
| photosensitizers | 0.460437 |
| tumor cells | 0.475849 |
| normal cells | 0.508255 |
| PDT | 0.970829 |
| Extracorporeal photopheresis | 0.455159 |
| large tumors | 0.503661 |
| porfimer sodium | 0.78695 |
| fiber optic cables | 0.493403 |
| light-emitting diodes | 0.456906 |
| nearby cells | 0.473123 |
| tumors | 0.505296 |
| Laser light | 0.464403 |
| cell lung cancer | 0.646935 |
| nearby cancer cells | 0.527607 |
|
CLICK HERE |
| 1747 |
National Cancer Institute |
Html |
en |
Asbestos Exposure and Cancer Risk |
A fact sheet about asbestos, asbestos-related diseases, and who to contact for more information. |
| Asbestos Ombudsman | 0.460839 |
| EPA state asbestos | 0.434096 |
| U.S. Consumer Product | 0.316535 |
| longer exposure time | 0.297627 |
| previous exposure | 0.27831 |
| asbestos textiles | 0.432289 |
| asbestos causes | 0.436856 |
| U.S. Department | 0.329349 |
| children’s exposure | 0.28171 |
| lung cancer | 0.280063 |
| asbestos programs | 0.405413 |
| asbestos minerals | 0.467011 |
| asbestos removal workers | 0.468852 |
| Asbestos School Hazard | 0.419561 |
| health care providers | 0.290173 |
| asbestos-related diseases | 0.348349 |
| health hazards | 0.295432 |
| human health effects | 0.27966 |
| asbestos exposure increase | 0.500132 |
| asbestos mines | 0.425258 |
| serpentine asbestos | 0.481061 |
| asbestos mining | 0.432341 |
| Asbestos page | 0.442685 |
| Federal agency | 0.290215 |
|
| Environmental Protection Agency | 0.377868 |
| OSHA’s Asbestos | 0.42031 |
| health effects | 0.305637 |
| Preventing Asbestos Exposure | 0.47948 |
| Product Safety Commission | 0.317357 |
| asbestos | 0.915525 |
| asbestos fibers | 0.648932 |
| asbestos exposure | 0.842565 |
| U.S. Environmental Protection | 0.377874 |
| heavier exposure | 0.277348 |
| Occupational Safety | 0.288197 |
| exposure history | 0.275525 |
| asbestos products | 0.436695 |
| amphibole asbestos | 0.479754 |
| Asbestos Hazard Emergency | 0.41964 |
| asbestos-related disease | 0.298672 |
| tiny asbestos fibers | 0.468171 |
| Health Administration | 0.283037 |
| occupational asbestos exposure | 0.500171 |
| Consumer Product Safety | 0.316531 |
| health | 0.344549 |
| Chrysotile asbestos | 0.460267 |
| information | 0.278169 |
| risk | 0.275773 |
|
CLICK HERE |
| 1811 |
National Cancer Institute |
Html |
es |
Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de varios tumores de encéfalo infantiles. |
| Altekruse SF | 0.447856 |
| American Academy | 0.440446 |
| Brain Tumor Registry | 0.477956 |
| pediatric cancer | 0.464838 |
| plexo coroideo | 0.50432 |
| largo plazo | 0.465315 |
| cancer center | 0.498759 |
| Children's National Health | 0.432864 |
| Declining childhood | 0.43143 |
| astrocitomas pilocÃticos | 0.47055 |
| Instituto Nacional | 0.460068 |
| Reifenberger G | 0.447846 |
| World Health Organization | 0.488687 |
| Health Organization Classification | 0.496391 |
| Pediatric Brain Tumor | 0.46738 |
| tumor embrionario | 0.530794 |
| SAI Tratamiento | 0.438882 |
| tumores glioneuronales papilares | 0.533183 |
| Children's Oncology Group | 0.486579 |
| Childhood Cancer Survivor | 0.446412 |
| SNC primarios | 0.433523 |
| central nervous system | 0.795553 |
| pdq correspondiente tipo | 0.466293 |
| Smith MA | 0.441598 |
| Acta Neuropathol | 0.450438 |
|
| long-term survivors | 0.443577 |
| tumores papilares | 0.526133 |
| Organización Mundial | 0.435085 |
| United States | 0.447735 |
| subtipo patológico sumario | 0.46642 |
| Neuro Oncol | 0.509938 |
| PDQ Descripción | 0.456005 |
| Pediatr Blood Cancer | 0.436965 |
| PDQ Efectos tardÃos | 0.580122 |
| National Cancer Institute | 0.479004 |
| Pollack IF | 0.449126 |
| tumor atÃpico | 0.44433 |
| Clin Oncol | 0.579132 |
| nervous system tumors | 0.447762 |
| sistema nervioso central | 0.82435 |
| childhood brain tumors | 0.461864 |
| brain tumor | 0.932348 |
| Kimmel Comprehensive Cancer | 0.433441 |
| Perry A | 0.444221 |
| tumores embrionarios | 0.61933 |
| newly diagnosed | 0.441805 |
| espinal infantiles recién | 0.46155 |
| childhood central nervous | 0.442376 |
| Wilmot Cancer Center | 0.432289 |
|
CLICK HERE |
| 1871 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del carcinoma de sitio primario desconocido. |
| cáncer epitelial versus | 0.404134 |
| Greco FA | 0.432795 |
| unknown primary tumours | 0.414817 |
| cisplatin-based combination chemotherapy | 0.404363 |
| unknown primary site | 0.721557 |
| Pavlidis N | 0.405224 |
| Breast carcinoma presenting | 0.411406 |
| unknown primary origin | 0.450607 |
| Hainsworth JD | 0.442528 |
| Metastatic malignant melanoma | 0.405856 |
| Cancer Res | 0.404192 |
| Radiat Oncol Biol | 0.414855 |
| neuroendocrine carcinoma | 0.415368 |
| Natl Cancer Inst | 0.417117 |
| poorly differentiated | 0.438667 |
| Melanoma from unknown | 0.410685 |
| serous papillary carcinoma | 0.405287 |
| patients with | 0.456873 |
| gene expression profiling | 0.404698 |
| unknown primary carcinoma | 0.451216 |
| carcinoma nasofarÃngeo | 0.409399 |
| poorly differentiated carcinoma | 0.41977 |
| cervical lymph | 0.404293 |
| patients with unknown | 0.4336 |
| Rodriguez E | 0.405003 |
|
| presenting as axillary | 0.404521 |
| metastases from unknown | 0.428245 |
| Unknown primary melanoma | 0.416245 |
| Abbruzzese MC | 0.404845 |
| Curr Probl Cancer | 0.404442 |
| primary neoplasm | 0.406005 |
| or undiscovered primary | 0.406863 |
| from unknown primary | 0.455678 |
| primary tumor site | 0.417993 |
| Surg Oncol | 0.405079 |
| PDQ Tratamiento | 0.416061 |
| Intern Med | 0.413673 |
| nasopharyngeal carcinoma | 0.405469 |
| Clin Oncol | 0.44391 |
| Johnson DH | 0.404766 |
| unknown primary | 0.993061 |
| Oncol Biol Phys | 0.415244 |
| with unknown primary | 0.46599 |
| metastatic adenocarcinomas | 0.408539 |
| unknown primary tumor | 0.442645 |
| germ cell tumors | 0.405207 |
| carcinoma presenting as | 0.411228 |
| occult primary carcinoma | 0.410287 |
| cancer incidence | 0.406991 |
|
CLICK HERE |
| 1982 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de tiroides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides. |
| glándula tiroides | 0.908295 |
| estadios iva | 0.233602 |
| siguientes procedimientos | 0.206098 |
| ganglios linfáticos.ampliar cáncer | 0.716308 |
| hormona tiroidea | 0.292738 |
| radioterapia intraoperatoria | 0.215525 |
| siguientes aspectos | 0.243621 |
| menos.ampliar cáncer | 0.315655 |
| gen ret | 0.208945 |
| estadio ii | 0.465746 |
| enfermedad tiroidea | 0.223963 |
| ganglio linfático centinela | 0.278708 |
| vÃa oral | 0.205075 |
| rayos x | 0.221349 |
| estadio ivb | 0.462997 |
| estadio ivc | 0.408027 |
| enlace drugs approved | 0.226007 |
| ondas sonoras | 0.222594 |
| estadio iva | 0.373015 |
| órgano fonador | 0.446375 |
| National Cancer Institute | 0.204974 |
|
| tiroides causa efectos | 0.252932 |
| endocrina múltiple tipo | 0.287058 |
| hormonas tiroideas | 0.209751 |
| Instituto Nacional | 0.209158 |
| PDQ Tratamiento | 0.229219 |
| antecedentes familiares | 0.2071 |
| pacientes pastillas | 0.209381 |
| siguientes funciones | 0.210244 |
| Physician Data Query | 0.218087 |
| estadio iii | 0.401226 |
| centÃmetros.ampliar cáncer | 0.275936 |
| suficiente hormona tiroidea | 0.209562 |
| nódulo tiroideo | 0.292185 |
| Thyroid Cancer | 0.21393 |
| hormona calcitonina | 0.209835 |
| pequeña dosis | 0.204395 |
| pequeña parte | 0.2042 |
| células tiroideas | 0.225287 |
| cuerpo.ampliar cáncer | 0.277585 |
| nódulos tiroideos | 0.301973 |
| tiroides.ampliar cáncer | 0.26979 |
|
CLICK HERE |
| 2063 |
National Cancer Institute |
Html |
es |
Radón y cáncer |
Hoja informativa acerca del radón, un gas radiactivo sin olor, y su posible asociación con el cáncer, y cómo realizar pruebas de detección del radón en el hogar. |
| residential radon case-control | 0.38371 |
| Health Risks | 0.326257 |
| residential radon | 0.683536 |
| elevada exposición | 0.322129 |
| American case-control studies | 0.325499 |
| Kansas State University | 0.319808 |
| lung cancer | 0.82038 |
| largo plazo | 0.437964 |
| Hill D | 0.332319 |
| Scandinavian Journal | 0.348044 |
| persons with lung | 0.339213 |
| Danish study | 0.316865 |
| Environmental Epidemiology | 0.320216 |
| Darby S | 0.336246 |
| collaborative analysis | 0.317051 |
| Environmental Health | 0.355768 |
| pequeñas partÃculas | 0.315096 |
| mundo inhala radón | 0.518177 |
| Lubin JH | 0.346614 |
| combined analysis | 0.316876 |
| Estados Unidos | 0.584661 |
| likely carcinogen | 0.314203 |
| Family From Radon | 0.368415 |
| elementos quÃmicos uranio | 0.332786 |
| PubMed Abstract | 0.939015 |
|
| Field RW | 0.336674 |
| altas concentraciones | 0.370467 |
| Cancer Journal | 0.333846 |
| Environmental Protection Agency | 0.326738 |
| National Radon Hotline | 0.369701 |
| Health Effects | 0.325858 |
| radón causa | 0.50069 |
| Public Health | 0.325273 |
| concentración promedio | 0.346248 |
| epidemiologic studies | 0.342525 |
| disponibles pruebas | 0.317342 |
| Exposure Analysis | 0.331287 |
| Health Physics | 0.355359 |
| BEIR VI | 0.314333 |
| gas radón | 0.662121 |
| Protecting Yourself | 0.31429 |
| corto plazo | 0.315556 |
| Residential radon gas | 0.389098 |
| risk among german | 0.327785 |
| persons without lung | 0.339772 |
| única forma | 0.341742 |
| Samet JM | 0.31548 |
| Retrieved October | 0.315338 |
| Zielinski JM | 0.315284 |
|
CLICK HERE |
| 3426 |
National Cancer Institute |
Html |
es |
El uso de la hipertermia en el tratamiento del cáncer |
Hoja informativa que explica en qué consiste la hipertermia (el tratamiento de los tumores con altas temperaturas) y sus efectos secundarios. |
| Lippincott Williams | 0.53777 |
| Lancet Oncology | 0.561914 |
| Gunderson LL | 0.539005 |
| Bast RC Jr | 0.559948 |
| Hildebrandt B | 0.608355 |
| Zee J | 0.537016 |
| undergoing surgical debulking | 0.565384 |
| causa efectos | 0.537555 |
| Gibbs FA Jr | 0.56087 |
| molecular basis | 0.53797 |
| intraperitoneal chemotherapy | 0.537405 |
| DeVita VT Jr | 0.563586 |
| termómetros minúsculos | 0.539825 |
| Kufe DW | 0.535758 |
| Kapp DS | 0.536798 |
| PubMed Abstract | 0.959153 |
| general medicamentos | 0.53615 |
| numerosos estudios | 0.552283 |
| Clinical Oncology | 0.559745 |
| Tepper JE | 0.538345 |
| International Journal | 0.535346 |
| Critical Reviews | 0.540202 |
| Isolation perfusion | 0.539903 |
| perfusión peritoneal hipertérmica | 0.626548 |
| hyperthermic peritoneal perfusion | 0.599527 |
|
| Pingpank JF | 0.537893 |
| numerosos obstáculos | 0.535929 |
| Libutti SK | 0.60375 |
| Carlson RW | 0.535964 |
| Wust P | 0.612473 |
| Decker Inc | 0.534795 |
| consecuencia quemaduras | 0.537822 |
| Issels RD | 0.537803 |
| combined treatment | 0.542204 |
| inserta pequeñas agujas | 0.572325 |
| también llamada terapia | 0.570859 |
| Churchill Livingstone | 0.537458 |
| Hellman S | 0.534905 |
| malignant peritoneal mesothelioma | 0.597049 |
| promising approach | 0.54123 |
| 6th ed | 0.538756 |
| cuello uterino | 0.631745 |
| Alexander HR | 0.602298 |
| Clinical Radiation Oncology | 0.587129 |
| altas temperaturas | 0.793884 |
| Ahlers O | 0.540177 |
| Hahn GM | 0.536167 |
| Roemer RB | 0.538179 |
| Sreenivasa G | 0.536365 |
|
CLICK HERE |
| 16812 |
National Cancer Institute |
Html |
es |
Cartílago (bovino y de tiburón) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| MIA Shark Powder | 0.309592 |
| libera productos | 0.304775 |
| Centro Nacional | 0.308058 |
| New Hampshire Avenue | 0.30568 |
| Drug Administration | 0.303513 |
| NCI Best Case | 0.309322 |
| vÃa oral | 0.453913 |
| datos bibliográficos pubmed | 0.30595 |
| células llamadas condrocitos | 0.314707 |
| siguientes preguntas | 0.30389 |
| numerosos productos | 0.303672 |
| cartÃlago bovino catrix | 0.352078 |
| National Cancer Institute | 0.306865 |
| siguientes riesgos | 0.304822 |
| Instituto Nacional | 0.331095 |
| Salud Complementaria | 0.311787 |
| Visuals Online | 0.304093 |
| complementarias revisa | 0.305499 |
|
| Physician Data Query | 0.323561 |
| Estados Unidos | 0.439543 |
| PDQ CartÃlago | 0.345303 |
| siguientes estudios | 0.31921 |
| libre uso | 0.304173 |
| cartÃlago bovino | 0.858349 |
| página manejo | 0.303836 |
| tiburón quizás | 0.3125 |
| numerosos estudios | 0.308556 |
| ¿El tratamiento | 0.308146 |
| tiburón llamada ae-941 | 0.314557 |
| siguientes datos | 0.30538 |
| ¿Los beneficios | 0.303518 |
| juntos cam | 0.30337 |
| Series Program | 0.303472 |
| vasos sanguÃneos | 0.95448 |
| medicina complementaria | 0.461353 |
|
CLICK HERE |